Tactile Systems Technology Inc
NASDAQ:TCMD

Watchlist Manager
Tactile Systems Technology Inc Logo
Tactile Systems Technology Inc
NASDAQ:TCMD
Watchlist
Price: 22.89 USD -0.56% Market Closed
Market Cap: $520.7m

Tactile Systems Technology Inc
PP&E Gross

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Tactile Systems Technology Inc
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Tactile Systems Technology Inc
NASDAQ:TCMD
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
PP&E Gross
$4.5B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
12%
Edwards Lifesciences Corp
NYSE:EW
PP&E Gross
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
PP&E Gross
$4.4B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
PP&E Gross
$11.8B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
PP&E Gross
$5.5B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tactile Systems Technology Inc
Glance View

Market Cap
520.7m USD
Industry
Health Care

Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.

TCMD Intrinsic Value
20.9 USD
Overvaluation 9%
Intrinsic Value
Price $22.89

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett